- Home
- NMS vs ACOG Comparison
NMS vs ACOG Comparison
Compare NMS & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- ACOG
- Stock Information
- Founded
- NMS 1993
- ACOG 2000
- Country
- NMS United States
- ACOG Canada
- Employees
- NMS N/A
- ACOG N/A
- Industry
- NMS Finance Companies
- ACOG
- Sector
- NMS Finance
- ACOG
- Exchange
- NMS Nasdaq
- ACOG Nasdaq
- Market Cap
- NMS 67.0M
- ACOG 80.3M
- IPO Year
- NMS N/A
- ACOG N/A
- Fundamental
- Price
- NMS $11.27
- ACOG $8.19
- Analyst Decision
- NMS
- ACOG Strong Buy
- Analyst Count
- NMS 0
- ACOG 1
- Target Price
- NMS N/A
- ACOG $20.00
- AVG Volume (30 Days)
- NMS 12.0K
- ACOG 71.0K
- Earning Date
- NMS 01-01-0001
- ACOG 08-14-2025
- Dividend Yield
- NMS 4.11%
- ACOG N/A
- EPS Growth
- NMS N/A
- ACOG N/A
- EPS
- NMS N/A
- ACOG N/A
- Revenue
- NMS N/A
- ACOG $4,586,341.00
- Revenue This Year
- NMS N/A
- ACOG N/A
- Revenue Next Year
- NMS N/A
- ACOG $149.89
- P/E Ratio
- NMS N/A
- ACOG N/A
- Revenue Growth
- NMS N/A
- ACOG N/A
- 52 Week Low
- NMS $9.21
- ACOG $3.75
- 52 Week High
- NMS $12.18
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- NMS 47.82
- ACOG 39.89
- Support Level
- NMS $11.19
- ACOG $7.79
- Resistance Level
- NMS $11.45
- ACOG $10.10
- Average True Range (ATR)
- NMS 0.11
- ACOG 0.83
- MACD
- NMS -0.01
- ACOG -0.12
- Stochastic Oscillator
- NMS 32.08
- ACOG 32.03
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.